{"hands_on_practices": [{"introduction": "A screening test's sensitivity ($Se$) and specificity ($Sp$) are intrinsic characteristics, but their real-world predictive power depends critically on the disease prevalence ($\\pi$) in the screened population. This fundamental exercise [@problem_id:4889589] guides you through deriving the Positive Predictive Value ($PPV$) and Negative Predictive Value ($NPV$) from first principles. By performing this calculation, you will uncover the often counterintuitive impact of low prevalence on test interpretation, a crucial insight for patient counseling and managing downstream diagnostic resources.", "problem": "A public health system is considering a population-based screening program for an asymptomatic cancer using a single-step test applied to an average-risk adult population. The test characteristics, established in large validation cohorts, are sensitivity $Se=0.90$ and specificity $Sp=0.95$. The target population has a disease prevalence $\\pi=0.01$. Starting from the fundamental definitions of sensitivity, specificity, prevalence, and conditional probability, and without invoking any pre-memorized shortcut formulas, derive expressions for the positive predictive value $PPV$ and the negative predictive value $NPV$ in terms of $Se$, $Sp$, and $\\pi$, and then compute their numerical values for the given parameters. Finally, interpret how the magnitudes of $PPV$ and $NPV$ should guide patient counseling and the anticipated use of downstream confirmatory diagnostics in a real-world screening program.\n\nReport $PPV$ and $NPV$ as decimals (no percent sign), rounded to four significant figures. In the final answer, present both numbers as a row matrix $(PPV,\\,NPV)$.", "solution": "The problem statement is evaluated for validity prior to attempting a solution.\n\n### Step 1: Extract Givens\n-   Sensitivity of the test: $Se = 0.90$\n-   Specificity of the test: $Sp = 0.95$\n-   Prevalence of the disease in the target population: $\\pi = 0.01$\n-   Task 1: Derive expressions for Positive Predictive Value ($PPV$) and Negative Predictive Value ($NPV$) from fundamental definitions.\n-   Task 2: Compute numerical values for $PPV$ and $NPV$.\n-   Task 3: Interpret the significance of the calculated $PPV$ and $NPV$ values for patient counseling and downstream diagnostic planning.\n-   Rounding instruction: Report $PPV$ and $NPV$ as decimals rounded to four significant figures.\n-   Final answer format: A row matrix $(\\text{PPV}, \\text{NPV})$.\n\n### Step 2: Validate Using Extracted Givens\n-   **Scientifically Grounded**: The problem is based on fundamental principles of probability theory (specifically, Bayes' theorem) as applied to epidemiology and medical diagnostics. The concepts of sensitivity, specificity, prevalence, $PPV$, and $NPV$ are standard, well-defined metrics in medicine and public health. The provided numerical values are realistic for a screening test for a low-prevalence condition.\n-   **Well-Posed**: The problem is clearly stated and provides all necessary information to derive the required expressions and compute the numerical values. A unique, stable, and meaningful solution exists.\n-   **Objective**: The problem is expressed using precise, standard, and unbiased terminology. It is free of subjective or opinion-based statements.\n\n### Step 3: Verdict and Action\nThe problem is scientifically grounded, well-posed, and objective. It contains no contradictions, ambiguities, or invalid premises. Therefore, the problem is **valid**. A full solution will be provided.\n\n### Solution Derivation\n\nWe begin by formally defining the events and probabilities based on the provided information.\nLet $D$ be the event that an individual from the population has the disease (cancer), and $D^c$ be the event that the individual does not have the disease.\nLet $T^+$ be the event that the test result is positive, and $T^-$ be the event that the test result is negative.\n\nFrom the problem statement, we can translate the given parameters into conditional probabilities:\n1.  **Prevalence ($\\pi$)**: The a priori probability that a randomly selected individual has the disease.\n    $$P(D) = \\pi = 0.01$$\n    The probability of not having the disease is therefore:\n    $$P(D^c) = 1 - P(D) = 1 - \\pi = 1 - 0.01 = 0.99$$\n\n2.  **Sensitivity ($Se$)**: The probability of a positive test result given that the individual has the disease. This is the true positive rate.\n    $$Se = P(T^+ | D) = 0.90$$\n\n3.  **Specificity ($Sp$)**: The probability of a negative test result given that the individual does not have the disease. This is the true negative rate.\n    $$Sp = P(T^- | D^c) = 0.95$$\n\nFrom these definitions, we can also define the complementary probabilities:\n-   The false negative rate (FNR), the probability of a negative test in a diseased individual, is:\n    $$P(T^- | D) = 1 - P(T^+ | D) = 1 - Se$$\n-   The false positive rate (FPR), the probability of a positive test in a disease-free individual, is:\n    $$P(T^+ | D^c) = 1 - P(T^- | D^c) = 1 - Sp$$\n\nOur objective is to derive expressions for the Positive Predictive Value ($PPV$) and the Negative Predictive Value ($NPV$).\n\n**1. Derivation of Positive Predictive Value ($PPV$)**\nThe $PPV$ is the probability that an individual has the disease given that they received a positive test result. Formally, this is the conditional probability $P(D | T^+)$.\nUsing the definition of conditional probability (Bayes' theorem):\n$$PPV = P(D | T^+) = \\frac{P(D \\cap T^+)}{P(T^+)}$$\nThe numerator represents the joint probability of having the disease and testing positive. It can be expressed as:\n$$P(D \\cap T^+) = P(T^+ | D) P(D) = Se \\cdot \\pi$$\nThe denominator, $P(T^+)$, is the total probability of receiving a positive test result in the population. We find this using the law of total probability, by summing over the two mutually exclusive states (having the disease or not having the disease):\n$$P(T^+) = P(T^+ \\cap D) + P(T^+ \\cap D^c)$$\n$$P(T^+) = P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)$$\nSubstituting the known terms:\n$$P(T^+) = (Se \\cdot \\pi) + ((1 - Sp) \\cdot (1 - \\pi))$$\nNow, we can assemble the final expression for $PPV$:\n$$PPV = \\frac{P(T^+ | D) P(D)}{P(T^+ | D) P(D) + P(T^+ | D^c) P(D^c)} = \\frac{Se \\cdot \\pi}{(Se \\cdot \\pi) + ((1 - Sp) \\cdot (1 - \\pi))}$$\n\n**2. Derivation of Negative Predictive Value ($NPV$)**\nThe $NPV$ is the probability that an individual does not have the disease given that they received a negative test result. Formally, this is the conditional probability $P(D^c | T^-)$.\nUsing the definition of conditional probability:\n$$NPV = P(D^c | T^-) = \\frac{P(D^c \\cap T^-)}{P(T^-)}$$\nThe numerator is the joint probability of not having the disease and testing negative:\n$$P(D^c \\cap T^-) = P(T^- | D^c) P(D^c) = Sp \\cdot (1 - \\pi)$$\nThe denominator, $P(T^-)$, is the total probability of receiving a negative test result. Using the law of total probability:\n$$P(T^-) = P(T^- \\cap D^c) + P(T^- \\cap D)$$\n$$P(T^-) = P(T^- | D^c) P(D^c) + P(T^- | D) P(D)$$\nSubstituting the known terms:\n$$P(T^-) = (Sp \\cdot (1 - \\pi)) + ((1 - Se) \\cdot \\pi)$$\nAssembling the final expression for $NPV$:\n$$NPV = \\frac{P(T^- | D^c) P(D^c)}{P(T^- | D^c) P(D^c) + P(T^- | D) P(D)} = \\frac{Sp \\cdot (1 - \\pi)}{(Sp \\cdot (1 - \\pi)) + ((1 - Se) \\cdot \\pi)}$$\n\n### Numerical Computation\nWe now substitute the given values: $Se=0.90$, $Sp=0.95$, and $\\pi=0.01$.\n\n**Computation of $PPV$:**\n$$PPV = \\frac{0.90 \\cdot 0.01}{(0.90 \\cdot 0.01) + ((1 - 0.95) \\cdot (1 - 0.01))}$$\n$$PPV = \\frac{0.009}{(0.009) + (0.05 \\cdot 0.99)}$$\n$$PPV = \\frac{0.009}{0.009 + 0.0495}$$\n$$PPV = \\frac{0.009}{0.0585} \\approx 0.15384615...$$\nRounding to four significant figures, $PPV = 0.1538$.\n\n**Computation of $NPV$:**\n$$NPV = \\frac{0.95 \\cdot (1 - 0.01)}{(0.95 \\cdot (1 - 0.01)) + ((1 - 0.90) \\cdot 0.01)}$$\n$$NPV = \\frac{0.95 \\cdot 0.99}{(0.95 \\cdot 0.99) + (0.10 \\cdot 0.01)}$$\n$$NPV = \\frac{0.9405}{0.9405 + 0.001}$$\n$$NPV = \\frac{0.9405}{0.9415} \\approx 0.99893786...$$\nRounding to four significant figures, $NPV = 0.9989$.\n\n### Interpretation\nThe calculated values of $PPV$ and $NPV$ have profound implications for clinical practice.\n\n-   **Positive Predictive Value ($PPV \\approx 0.1538$):** The $PPV$ is strikingly low. It signifies that for an individual from this average-risk population who receives a positive screening test result, the probability that they actually have the cancer is only about $15.4\\%$. Conversely, there is an approximate $84.6\\%$ chance that the positive result is a false positive. This phenomenon is a direct mathematical consequence of applying a test with imperfect specificity to a population with low disease prevalence.\n    -   **Patient Counseling:** It is imperative for the clinician to explain that a positive screening test is not a diagnosis. It is a risk-stratification tool. The patient should be counseled that while their risk is now higher than the general population's, it is still far more likely that they do not have cancer. This communication is critical to manage patient anxiety and ensure adherence to follow-up.\n    -   **Downstream Diagnostics:** The low $PPV$ means that a large volume of confirmatory diagnostic procedures (e.g., biopsies, more advanced imaging) will be required. Specifically, the ratio of positive screens to true positive cases is $1/PPV \\approx 1/0.1538 \\approx 6.5$. For every $6.5$ individuals sent for confirmatory testing, only $1$ will be found to have the disease. The health system must have adequate capacity and resources to manage this large burden of follow-up testing on individuals who are, in fact, disease-free.\n\n-   **Negative Predictive Value ($NPV \\approx 0.9989$):** The $NPV$ is extremely high, approaching $1$. This indicates that for an individual receiving a negative test result, the probability that they are truly free of the disease is approximately $99.9\\%$.\n    -   **Patient Counseling:** A negative result is highly reassuring. The clinician can confidently inform the patient that it is extremely unlikely they have the cancer. The patient can be advised to return to the standard screening interval appropriate for their risk profile.\n    -   **Downstream Diagnostics:** A negative result effectively rules out the disease in the screened individual. No further immediate diagnostic workup is warranted based on this test result, which avoids unnecessary procedures and costs for the vast majority of the screened population.\n\nIn summary, for a low-prevalence disease, an effective screening test must have a very high $NPV$ to provide reassurance, but even with good sensitivity and specificity, it will likely have a low $PPV$. This mandates careful patient communication and robust planning for confirmatory diagnostics.", "answer": "$$\n\\boxed{\\begin{pmatrix} 0.1538 & 0.9989 \\end{pmatrix}}\n$$", "id": "4889589"}, {"introduction": "For many screening tests based on a continuous biomarker, sensitivity and specificity are not fixed but represent a trade-off determined by the chosen positivity threshold. This practice [@problem_id:4889558] models this crucial relationship using a hypothetical scenario with normally distributed biomarker data, demonstrating how lowering a threshold to increase sensitivity invariably decreases specificity. You will quantify how this trade-off directly impacts the Positive Predictive Value, providing a foundational understanding for test optimization and the principles behind Receiver Operating Characteristic (ROC) curve analysis.", "problem": "A continuous biomarker $X$ is used in a population-based cancer screening program where higher values of $X$ indicate a greater likelihood of disease. Assume the following scientifically plausible measurement model: the biomarker among individuals with cancer satisfies $X \\mid D \\sim \\mathcal{N}(\\mu_{1}, \\sigma^{2})$ with $\\mu_{1} = 2$ and $\\sigma = 1$, and among individuals without cancer satisfies $X \\mid \\neg D \\sim \\mathcal{N}(\\mu_{0}, \\sigma^{2})$ with $\\mu_{0} = 0$ and $\\sigma = 1$. A screening test declares a positive result if $X \\geq c$, where $c$ is a positivity threshold. Using only core definitions of Sensitivity (Se), Specificity (Sp), and Bayesâ€™ theorem for Positive Predictive Value (PPV), and properties of the normal cumulative distribution function, do the following:\n\n1. Derive general expressions for $Se(c)$ and $Sp(c)$ as functions of the threshold $c$ and prove, from first principles, that decreasing $c$ increases $Se(c)$ and decreases $Sp(c)$.\n\n2. Consider a low disease prevalence (prevalence denoted by $\\pi$) typical of population-based screening, with $\\pi = 0.02$. Compute the Positive Predictive Value (PPV), defined as the posterior probability of disease given a positive test, at two thresholds: $c_{1} = 1.5$ and $c_{2} = 0.5$. Then quantify the effect of moving the positivity threshold to increase sensitivity by reporting the change in PPV, defined as $PPV(c_{2}) - PPV(c_{1})$, expressed as a decimal fraction. Round your final reported change to four significant figures.", "solution": "The problem statement will first be validated for scientific soundness, clarity, and completeness.\n\n### Step 1: Extract Givens\n-   A continuous biomarker $X$ is used for cancer screening.\n-   Distribution of $X$ among individuals with cancer ($D$): $X \\mid D \\sim \\mathcal{N}(\\mu_{1}, \\sigma^{2})$, where $\\mu_{1} = 2$ and $\\sigma = 1$.\n-   Distribution of $X$ among individuals without cancer ($\\neg D$): $X \\mid \\neg D \\sim \\mathcal{N}(\\mu_{0}, \\sigma^{2})$, where $\\mu_{0} = 0$ and $\\sigma = 1$.\n-   A screening test is positive if $X \\geq c$, where $c$ is a positivity threshold.\n-   Sensitivity is denoted by $Se$.\n-   Specificity is denoted by $Sp$.\n-   Positive Predictive Value is denoted by $PPV$.\n-   Disease prevalence is $\\pi = P(D) = 0.02$.\n-   Two thresholds are considered: $c_{1} = 1.5$ and $c_{2} = 0.5$.\n-   The task requires calculation of the change in PPV: $PPV(c_{2}) - PPV(c_{1})$.\n-   The final numerical answer must be rounded to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\n-   **Scientifically Grounded**: The problem is well-grounded in biostatistics and epidemiology. Modeling a biomarker with normal distributions for diseased and non-diseased populations is a standard and scientifically plausible assumption. The definitions of sensitivity, specificity, and positive predictive value are fundamental concepts in medical diagnostics. The values for means, standard deviation, and prevalence are realistic for a representative population screening scenario.\n-   **Well-Posed**: The problem is fully specified. All necessary parameters ($\\mu_1, \\mu_0, \\sigma, \\pi$) and definitions required for the derivation and calculation are provided. The questions are precise and lead to a unique, meaningful solution.\n-   **Objective**: The language is objective and employs standard, unambiguous terminology from statistics and medicine.\n\n### Step 3: Verdict and Action\nThe problem is scientifically valid, well-posed, and objective. It does not violate any of the specified invalidity criteria. Therefore, a solution will be provided.\n\n### Part 1: Derivations and Proofs\n\nLet $\\Phi(z)$ be the cumulative distribution function (CDF) of the standard normal distribution $\\mathcal{N}(0, 1)$, and let $\\phi(z)$ be its probability density function (PDF).\n\n**Sensitivity, $Se(c)$**\n\nSensitivity is the probability of a positive test result given that the individual has the disease.\n$$Se(c) = P(\\text{Test Positive} \\mid D) = P(X \\geq c \\mid D)$$\nGiven $X \\mid D \\sim \\mathcal{N}(\\mu_{1}, \\sigma^{2})$, we standardize the variable $X$:\n$$Se(c) = P\\left(\\frac{X - \\mu_1}{\\sigma} \\geq \\frac{c - \\mu_1}{\\sigma} \\mid D\\right)$$\nLet $Z = \\frac{X - \\mu_1}{\\sigma}$, where $Z \\sim \\mathcal{N}(0, 1)$.\n$$Se(c) = P\\left(Z \\geq \\frac{c - \\mu_1}{\\sigma}\\right) = 1 - P\\left(Z < \\frac{c - \\mu_1}{\\sigma}\\right)$$\nThus, the general expression for sensitivity is:\n$$Se(c) = 1 - \\Phi\\left(\\frac{c - \\mu_1}{\\sigma}\\right)$$\n\n**Specificity, $Sp(c)$**\n\nSpecificity is the probability of a negative test result given that the individual does not have the disease.\n$$Sp(c) = P(\\text{Test Negative} \\mid \\neg D) = P(X < c \\mid \\neg D)$$\nGiven $X \\mid \\neg D \\sim \\mathcal{N}(\\mu_{0}, \\sigma^{2})$, we standardize the variable $X$:\n$$Sp(c) = P\\left(\\frac{X - \\mu_0}{\\sigma} < \\frac{c - \\mu_0}{\\sigma} \\mid \\neg D\\right)$$\nLet $Z' = \\frac{X - \\mu_0}{\\sigma}$, where $Z' \\sim \\mathcal{N}(0, 1)$.\n$$Sp(c) = P\\left(Z' < \\frac{c - \\mu_0}{\\sigma}\\right)$$\nThus, the general expression for specificity is:\n$$Sp(c) = \\Phi\\left(\\frac{c - \\mu_0}{\\sigma}\\right)$$\n\n**Proof of Monotonicity**\n\nTo prove that decreasing the threshold $c$ increases $Se(c)$ and decreases $Sp(c)$, we examine the derivatives of $Se(c)$ and $Sp(c)$ with respect to $c$. The derivative of the standard normal CDF, $\\frac{d}{dz}\\Phi(z)$, is its PDF, $\\phi(z)$.\n\nFor $Se(c)$:\n$$\\frac{d}{dc}Se(c) = \\frac{d}{dc}\\left[1 - \\Phi\\left(\\frac{c - \\mu_1}{\\sigma}\\right)\\right] = -\\frac{d}{dc}\\Phi\\left(\\frac{c - \\mu_1}{\\sigma}\\right)$$\nUsing the chain rule:\n$$\\frac{d}{dc}Se(c) = -\\phi\\left(\\frac{c - \\mu_1}{\\sigma}\\right) \\cdot \\frac{d}{dc}\\left(\\frac{c - \\mu_1}{\\sigma}\\right) = -\\phi\\left(\\frac{c - \\mu_1}{\\sigma}\\right) \\cdot \\frac{1}{\\sigma}$$\nSince the standard normal PDF $\\phi(z)$ is strictly positive for all $z \\in \\mathbb{R}$ and the standard deviation $\\sigma$ is positive, the derivative $\\frac{d}{dc}Se(c)$ is always negative. A function with a negative derivative is monotonically decreasing. Therefore, as $c$ increases, $Se(c)$ decreases, and conversely, as $c$ decreases, $Se(c)$ increases.\n\nFor $Sp(c)$:\n$$\\frac{d}{dc}Sp(c) = \\frac{d}{dc}\\Phi\\left(\\frac{c - \\mu_0}{\\sigma}\\right)$$\nUsing the chain rule:\n$$\\frac{d}{dc}Sp(c) = \\phi\\left(\\frac{c - \\mu_0}{\\sigma}\\right) \\cdot \\frac{d}{dc}\\left(\\frac{c - \\mu_0}{\\sigma}\\right) = \\phi\\left(\\frac{c - \\mu_0}{\\sigma}\\right) \\cdot \\frac{1}{\\sigma}$$\nSince $\\phi(z) > 0$ and $\\sigma > 0$, the derivative $\\frac{d}{dc}Sp(c)$ is always positive. A function with a positive derivative is monotonically increasing. Therefore, as $c$ increases, $Sp(c)$ increases, and conversely, as $c$ decreases, $Sp(c)$ decreases. This completes the proofs.\n\n### Part 2: PPV Calculation\n\nThe Positive Predictive Value, $PPV(c)$, is the probability of having the disease given a positive test result, $P(D \\mid X \\geq c)$. Using Bayes' theorem:\n$$PPV(c) = \\frac{P(X \\geq c \\mid D) P(D)}{P(X \\geq c)}$$\nThe denominator is expanded using the law of total probability:\n$$P(X \\geq c) = P(X \\geq c \\mid D)P(D) + P(X \\geq c \\mid \\neg D)P(\\neg D)$$\nRecognizing the terms:\n- $P(D) = \\pi$\n- $P(\\neg D) = 1 - \\pi$\n- $P(X \\geq c \\mid D) = Se(c)$\n- $P(X \\geq c \\mid \\neg D) = 1 - P(X < c \\mid \\neg D) = 1 - Sp(c)$ (this is the false positive rate)\n\nSubstituting these into the Bayes' formula yields the expression for $PPV(c)$:\n$$PPV(c) = \\frac{Se(c) \\cdot \\pi}{Se(c) \\cdot \\pi + (1 - Sp(c)) \\cdot (1 - \\pi)}$$\n\nWe are given $\\mu_1 = 2$, $\\mu_0 = 0$, $\\sigma = 1$, and $\\pi = 0.02$.\n\nFirst, calculate $Se$ and $Sp$ for $c_{1} = 1.5$:\n$$Se(c_1) = 1 - \\Phi\\left(\\frac{1.5 - 2}{1}\\right) = 1 - \\Phi(-0.5)$$\nUsing the property $\\Phi(-z) = 1 - \\Phi(z)$, we have $Se(c_1) = 1 - (1 - \\Phi(0.5)) = \\Phi(0.5)$.\n$$Sp(c_1) = \\Phi\\left(\\frac{1.5 - 0}{1}\\right) = \\Phi(1.5)$$\nUsing standard normal table values, $\\Phi(0.5) \\approx 0.691462$ and $\\Phi(1.5) \\approx 0.933193$.\n$$Se(c_1) \\approx 0.691462$$\n$$Sp(c_1) \\approx 0.933193$$\nNow, calculate $PPV(c_1)$:\n$$PPV(c_1) = \\frac{0.691462 \\cdot 0.02}{0.691462 \\cdot 0.02 + (1 - 0.933193) \\cdot (1 - 0.02)}$$\n$$PPV(c_1) = \\frac{0.01382924}{0.01382924 + (0.066807) \\cdot (0.98)} = \\frac{0.01382924}{0.01382924 + 0.06547086} = \\frac{0.01382924}{0.0793001} \\approx 0.174391$$\n\nNext, calculate $Se$ and $Sp$ for $c_{2} = 0.5$:\n$$Se(c_2) = 1 - \\Phi\\left(\\frac{0.5 - 2}{1}\\right) = 1 - \\Phi(-1.5) = \\Phi(1.5) \\approx 0.933193$$\n$$Sp(c_2) = \\Phi\\left(\\frac{0.5 - 0}{1}\\right) = \\Phi(0.5) \\approx 0.691462$$\nNow, calculate $PPV(c_2)$:\n$$PPV(c_2) = \\frac{0.933193 \\cdot 0.02}{0.933193 \\cdot 0.02 + (1 - 0.691462) \\cdot (1 - 0.02)}$$\n$$PPV(c_2) = \\frac{0.01866386}{0.01866386 + (0.308538) \\cdot (0.98)} = \\frac{0.01866386}{0.01866386 + 0.30236724} = \\frac{0.01866386}{0.3210311} \\approx 0.058137$$\n\nFinally, compute the change in PPV:\n$$\\Delta PPV = PPV(c_{2}) - PPV(c_{1}) \\approx 0.058137 - 0.174391 = -0.116254$$\nRounding to four significant figures, the change is $-0.1163$. This negative change indicates that while lowering the threshold from $c_1=1.5$ to $c_2=0.5$ increased sensitivity (from $\\approx 69\\%$ to $\\approx 93\\%$), it also substantially decreased the positive predictive value (from $\\approx 17.4\\%$ to $\\approx 5.8\\%$) due to a large increase in false positives.", "answer": "$$ \\boxed{-0.1163} $$", "id": "4889558"}, {"introduction": "Effective screening programs often involve repeated testing over many years, which introduces cumulative risks that are not apparent from a single test's performance. This hands-on problem [@problem_id:4889536] focuses on one of the most significant harms of longitudinal screening: the cumulative probability of a false-positive result. By modeling this scenario, you will develop a critical appreciation for how even a small per-screen false-positive rate can lead to a substantial cumulative burden on the healthy population over the lifetime of a screening program.", "problem": "A national program implements annual mammography screening for a cohort of women without breast cancer at baseline. To reduce aggregate harm from false-positive test results, the program stratifies participants into two mutually exclusive protocol groups based on pre-enrollment risk assessment and site capabilities. A proportion $w = 0.7$ of participants receives a standard protocol with per-screen false-positive probability $p_{1} = 0.10$, and the remaining proportion $1-w = 0.3$ receives a high-specificity protocol with per-screen false-positive probability $p_{2} = 0.05$. Each participant is scheduled for $n = 10$ independent annual screening rounds over a fixed horizon. Assume that, conditional on protocol group, the per-round false-positive probability is constant across rounds and that false-positive outcomes across rounds are independent for an individual. Also assume no incident cancers over the horizon (so that all positive results in this modeling exercise are false positives), and ignore loss to follow-up and mortality. \n\nUsing only the complement rule for probabilities and independence across rounds, derive from first principles an analytic expression for the population-average cumulative probability that a randomly selected participant experiences at least one false-positive result in the $n$ rounds, and then evaluate this expression numerically for the given parameter values $w$, $p_{1}$, $p_{2}$, and $n$. Express the final answer as a decimal number with no unit. Round your answer to four significant figures.", "solution": "The problem requires the derivation of an analytic expression for the population-average cumulative probability that a randomly selected participant experiences at least one false-positive result in $n$ rounds of screening, and then a numerical evaluation of this expression. The solution must be derived from first principles using the complement rule and independence.\n\nFirst, let us define the relevant events and parameters based on the problem statement.\nThe population of participants is stratified into two mutually exclusive groups:\n- Group 1: Standard protocol group. A proportion $w$ of participants are in this group.\n- Group 2: High-specificity protocol group. A proportion $1-w$ of participants are in this group.\n\nThe parameters are:\n- $w = 0.7$: Proportion of participants in Group 1.\n- $1-w = 0.3$: Proportion of participants in Group 2.\n- $p_1 = 0.10$: Per-screen false-positive probability for Group 1.\n- $p_2 = 0.05$: Per-screen false-positive probability for Group 2.\n- $n = 10$: Number of independent annual screening rounds.\n\nLet $A$ be the event that a randomly selected participant experiences at least one false-positive result in $n$ rounds. We want to find the probability of this event, $P(A)$.\nLet $G_1$ be the event that a randomly selected participant belongs to Group 1, and $G_2$ be the event that the participant belongs to Group 2. From the problem statement, we have:\n$$P(G_1) = w$$\n$$P(G_2) = 1 - w$$\n\nSince $G_1$ and $G_2$ form a partition of the sample space (they are mutually exclusive and exhaustive), we can use the law of total probability to find $P(A)$:\n$$P(A) = P(A|G_1) P(G_1) + P(A|G_2) P(G_2)$$\nwhere $P(A|G_1)$ is the conditional probability of event $A$ given the participant is in Group 1, and $P(A|G_2)$ is the conditional probability of event $A$ given the participant is in Group 2.\n\nThe problem requires us to use the complement rule. Let $A^c$ be the complement of event $A$. $A^c$ is the event that a participant experiences *zero* false-positive results in all $n$ rounds. The relationship between the probabilities is:\n$$P(A|G_i) = 1 - P(A^c|G_i) \\quad \\text{for } i \\in \\{1, 2\\}$$\n\nLet's calculate $P(A^c|G_1)$. This is the probability of having no false positives in $n$ rounds, given the participant is in Group 1. The probability of a false positive in any single round for a person in Group 1 is $p_1$. Therefore, the probability of *not* having a false positive (a negative result) in a single round is $1 - p_1$. Since the outcomes of the $n$ rounds are independent, the probability of having no false positives in all $n$ rounds is the product of the probabilities of having a negative result in each round:\n$$P(A^c|G_1) = (1 - p_1) \\times (1 - p_1) \\times \\dots \\times (1 - p_1) = (1 - p_1)^n$$\nUsing the complement rule, the probability of at least one false positive for a participant in Group 1 is:\n$$P(A|G_1) = 1 - (1 - p_1)^n$$\n\nSimilarly, for a participant in Group 2, the per-round false-positive probability is $p_2$. The probability of a negative result in a single round is $1 - p_2$. Due to independence across rounds, the probability of having no false positives in $n$ rounds is:\n$$P(A^c|G_2) = (1 - p_2)^n$$\nSo, the probability of at least one false positive for a participant in Group 2 is:\n$$P(A|G_2) = 1 - (1 - p_2)^n$$\n\nNow, we substitute these conditional probabilities back into the law of total probability equation. This yields the desired analytic expression for the population-average cumulative probability of at least one false positive:\n$$P(A) = \\left[1 - (1 - p_1)^n\\right] w + \\left[1 - (1 - p_2)^n\\right] (1 - w)$$\n\nThe final step is to evaluate this expression numerically using the given parameter values: $w = 0.7$, $p_1 = 0.10$, $p_2 = 0.05$, and $n = 10$.\nSubstituting the values:\n$$P(A) = \\left[1 - (1 - 0.10)^{10}\\right] (0.7) + \\left[1 - (1 - 0.05)^{10}\\right] (1 - 0.7)$$\n$$P(A) = \\left[1 - (0.90)^{10}\\right] (0.7) + \\left[1 - (0.95)^{10}\\right] (0.3)$$\nFirst, we calculate the values of the exponential terms:\n$$(0.90)^{10} \\approx 0.34867844$$\n$$(0.95)^{10} \\approx 0.59873694$$\nNext, we calculate the probabilities for each group:\n$$P(A|G_1) = 1 - (0.90)^{10} \\approx 1 - 0.34867844 = 0.65132156$$\n$$P(A|G_2) = 1 - (0.95)^{10} \\approx 1 - 0.59873694 = 0.40126306$$\nFinally, we compute the weighted average:\n$$P(A) \\approx (0.65132156)(0.7) + (0.40126306)(0.3)$$\n$$P(A) \\approx 0.45592509 + 0.12037892$$\n$$P(A) \\approx 0.57630401$$\nThe problem requires the answer to be rounded to four significant figures. The first four significant figures are $5$, $7$, $6$, and $3$. The fifth significant figure is $0$, so we round down (truncate).\n$$P(A) \\approx 0.5763$$", "answer": "$$\n\\boxed{0.5763}\n$$", "id": "4889536"}]}